PMID- 26834963
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2045-0869 (Print)
IS  - 2045-0877 (Electronic)
IS  - 2045-0869 (Linking)
VI  - 3
IP  - 1
DP  - 2016
TI  - Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced 
      sensitivities but increased controversies.
PG  - 53-66
AB  - In multiple endocrine neoplasia type 1 (MEN1) patients, a number of recent 
      studies compare the ability of different, new imaging modalities to existing 
      modalities to localize the important neuroendocrine tumors (NETs) that contribute 
      to their decreased life expectancy (pancreatic NETs [pNETs] and thymic 
      carcinoids). These included the use of (68)Ga-DOTATOC-PET/CT, endoscopic 
      ultrasound and MRI. The current paper analyzes these results in light of current 
      guidelines and controversies involved in the treatment/management of MEN1 
      patients. Particular attention is paid to results in these studies with thymic 
      carcinoids and nonfunctional pNETs/gastrinomas, which recent studies show are 
      particularly important in determining long-term survival. These studies show a 
      number of promising imaging results but also raise a number of controversies, 
      which will need to be addressed both in their use initially and for serial 
      studies in these patients.
FAU - Ito, Tetsuhide
AU  - Ito T
AD  - Department of Medicine & Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
FAU - Jensen, Robert T
AU  - Jensen RT
AD  - Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20817, USA.
LA  - eng
GR  - Z01 DK053101-20/Intramural NIH HHS/United States
GR  - Z01 DK053200-17/Intramural NIH HHS/United States
GR  - Z99 DK999999/Intramural NIH HHS/United States
PT  - Journal Article
DEP - 20160118
PL  - England
TA  - Int J Endocr Oncol
JT  - International journal of endocrine oncology
JID - 101648548
PMC - PMC4728712
MID - NIHMS752940
OTO - NOTNLM
OT  - MEN1
OT  - MRI
OT  - Zollinger-Ellison syndrome
OT  - endoscopic ultrasound
OT  - hyperparathyroidism
OT  - insulinoma
OT  - pancreatic neuroendocrine tumor
OT  - somatostatin-receptor scintigraphy
OT  - thymic carcinoid
COIS- Competing interests disclosure The authors have no other relevant affiliations or 
      financial involvement with any organization or entity with a financial interest 
      in or financial conflict with the subject matter or materials discussed in the 
      manuscript apart from those disclosed. No writing assistance was utilized in the 
      production of this manuscript.
EDAT- 2016/02/03 06:00
MHDA- 2016/02/03 06:01
PMCR- 2016/11/18
CRDT- 2016/02/03 06:00
PHST- 2016/02/03 06:00 [entrez]
PHST- 2016/02/03 06:00 [pubmed]
PHST- 2016/02/03 06:01 [medline]
PHST- 2016/11/18 00:00 [pmc-release]
AID - 10.2217/ije.15.29 [doi]
PST - ppublish
SO  - Int J Endocr Oncol. 2016;3(1):53-66. doi: 10.2217/ije.15.29. Epub 2016 Jan 18.